Compass Therapeutics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing was submitted March 21, 2024. Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company with no approved commercial products and no product revenue.
Business Context and Pipeline
- The company develops antibody-based oncology therapeutics focused on angiogenesis and immune-oncology mechanisms.
- CTX-009: DLL4 x VEGF-A bispecific antibody in a Phase 2 colorectal cancer trial and a randomized Phase 2/3 biliary tract cancer trial in the United States.
- CTX-471: CD137 agonist antibody. The monotherapy Phase 1 study was nearing completion, while the Phase 1b combination study with pembrolizumab had completed dose escalation and begun dose expansion.
- CTX-8371: PD-1 x PD-L1 bispecific antibody. The FDA cleared its IND in the fourth quarter of 2023, and the first-in-human Phase 1 trial was expected to dose its first patient by early second quarter 2024.
- The company had 32 employees as of December 31, 2023, including 19 primarily engaged in research and development and clinical activities.
Financial Performance and Liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $38.1 million | $30.0 million | +$8.1 million |
| General and administrative expense | $12.2 million | $11.7 million | +$0.6 million |
| Total operating expenses | $50.4 million | $41.7 million | +$8.7 million |
| Loss from operations | $(50.4) million | $(41.7) million | $(8.7) million |
| Other income | $7.9 million | $2.4 million | +$5.4 million |
| Net loss | $(42.5) million | $(39.2) million | $(3.3) million |
| Basic and diluted loss per share | $(0.33) | $(0.37) | Improved per share result due primarily to higher share count |
| Cash used in operating activities | $(40.6) million | $(34.1) million | Higher operating cash burn |
- Year-end cash and cash equivalents were $24.2 million, and marketable securities were $128.2 million, for total cash, cash equivalents and marketable securities of approximately $152.5 million.
- Management expects these resources to fund operating expenses and capital expenditures into mid-2026, based on current development plans and assumptions.
- Total assets were $156.9 million and total liabilities were $8.3 million at year-end. The filing does not disclose material conventional debt; liabilities primarily consisted of accounts payable, accrued expenses and operating lease obligations.
- Operating lease obligations totaled $1.7 million, and non-cancelable manufacturing commitments totaled $3.0 million. Total disclosed contractual commitments were $4.8 million.
- Stock-based compensation expense increased to $6.1 million from $5.3 million in 2022.
- The company reported no income tax expense. Deferred tax assets of $44.3 million were substantially offset by a $43.8 million valuation allowance.
- Margins are not meaningful because the company has no revenue; the company remains loss-making and pre-commercial.
Material Changes Versus 2022
- Research and development expense increased 27%, primarily because CTX-009 clinical and manufacturing costs increased by $10.7 million.
- CTX-009 program spending rose to $25.6 million from $13.1 million, while CTX-471 and CTX-8371 spending declined to $3.6 million and $4.0 million, respectively.
- Interest income increased to $7.9 million from $2.4 million, primarily because of higher interest rates and the company’s investment portfolio.
- Operating cash use increased by $6.5 million, while year-end cash and cash equivalents declined by $10.7 million. Marketable securities declined by $23.4 million as investments were used to fund operations and development.
- Financing activity was limited to approximately $3.0 million of net ATM proceeds in 2023, compared with $75.8 million of net proceeds from the 2022 PIPE offering.
- In the first quarter of 2024, the company sold 9.8 million shares through its ATM facility for $17.6 million of net proceeds, an important post-period financing event.
- In the fourth quarter of 2023, the company announced a leadership transition effective January 9, 2024: Vered Bisker-Leib became CEO, while Thomas Schuetz became President of Research and Development and Vice Chair of the board.
Guidance, Outlook, Risks and Unusual Items
- For CTX-009 in biliary tract cancer, enrollment in the Phase 2/3 trial was expected to be completed by mid-2024, with top-line data expected in the second half of 2024 and a potential BLA filing as early as the second half of 2025, depending on results.
- Initial Stage 1 results from the CTX-009 colorectal cancer Phase 2 trial were expected by mid-2024.
- The CTX-8371 Phase 1 trial was initiated in the first quarter of 2024, with first-patient dosing expected by early second quarter 2024.
- The company expects expenses and operating losses to increase as clinical programs advance and states that substantial additional financing will be required.
- Key risks include clinical-trial failure or delay, uncertain regulatory approval, limited patient enrollment, adverse events, reliance on contract research and manufacturing organizations, intellectual-property challenges, competition, cybersecurity incidents and the need for additional capital.
- CTX-009 clinical data are preliminary and from relatively small studies. Reported activity includes a 37.5% response rate in the first stage of a South Korean biliary tract cancer study, but these results may not predict outcomes in the randomized U.S. Phase 2/3 trial.
- The company has never generated product-sale revenue, has an accumulated deficit of $315.3 million, and may never become profitable.
- The independent auditor issued an unqualified opinion on the consolidated financial statements. Management reported effective internal control over financial reporting, but the auditor was not required to provide an attestation because Compass is an emerging growth company.
Most Important Facts for Investors to Verify
- Cash runway assumptions supporting funding into mid-2026 and the pace of quarterly operating cash burn.
- Timing, enrollment progress and top-line results for the CTX-009 biliary tract cancer and colorectal cancer trials.
- Whether CTX-009 efficacy and safety results are confirmed in randomized or larger studies.
- Clinical activity and safety findings from the CTX-471 pembrolizumab combination trial.
- Initial human safety, pharmacokinetic and efficacy data for CTX-8371.
- Future financing requirements, ATM usage, potential dilution and the terms of any strategic partnerships.
- Outstanding manufacturing commitments, license milestones, royalties and the scope and enforceability of licensed and owned patent rights.
- Post-period developments, including the $17.6 million of net ATM proceeds raised in the first quarter of 2024 and the January 2024 CEO transition.